ReviewCurrent opinion in virology2015
Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.
Review in Current opinion in virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Review
- Engineering the ADDomer Nanoparticle Vaccine Scaffold for Improved Assembly and Enhanced Stability.ACS synthetic biology · 2026Article
- Chimeric virus-like particles carrying the CLEC17A carbohydrate-recognition domain significantly reduce Macrobrachium rosenbergii nodavirus infection in Sf9 cells.Scientific reports · 2025Article
- The RNA Landscape of In Vivo-Assembled MS2 Virus-Like Particles as mRNA Carriers Reveals RNA Contamination from Host Viruses.Nano letters · 2025Article
- Review
- One-plasmid double-expression system for preparation of MS2 virus-like particles packaging SARS-CoV-2 RNA.Frontiers in cellular and infection microbiology · 2023Article
- Virus-like Particles: Fundamentals and Biomedical Applications.International journal of molecular sciences · 2022Review
- Development of Bacteriophage Virus-Like Particle Vaccines Displaying Conserved Epitopes of Dengue Virus Non-Structural Protein 1.Vaccines · 2021Article
- The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration.Vaccines · 2021Article
- Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide.Vaccines · 2020Article
- Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies.International journal of molecular sciences · 2020Review
- Active Delivery of VLPs Promotes Anti-Tumor Activity in a Mouse Ovarian Tumor Model.Small (Weinheim an der Bergstrasse, Germany) · 2020Article
- Synthetic biology for bioengineering virus-like particle vaccines.Biotechnology and bioengineering · 2019Review
- One-plasmid double-expression His-tag system for rapid production and easy purification of MS2 phage-like particles.Scientific reports · 2017Article
- Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery.Bioengineering & translational medicine · 2017Review
- Display of single-chain variable fragments on bacteriophage MS2 virus-like particles.Journal of nanobiotechnology · 2017Article
- Bacteriophages and Their Immunological Applications against Infectious Threats.Journal of immunology research · 2017Review
- Engineering virus-like particles as vaccine platforms.Current opinion in virology · 2016Review
- Oral Immunization of Rabbits with S. enterica Typhimurium Expressing Neisseria gonorrhoeae Filamentous Phage Φ6 Induces Bactericidal Antibodies Against N. gonorrhoeae.Scientific reports · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Display of epitopes on virus-like particles (VLPs) is a highly effective technique for enhancing the immunogenicity of antigens that are poorly immunogenic in their native context. VLP-based vaccines can be used to elicit long-lasting, high-titer antibody responses against diverse target antigens, even self-antigens. Most VLP platform-based vaccines are rationally engineered; specific target epitopes or domains are arrayed so that they are displayed at high-valency on the surface of VLPs. In this review, we describe an alternate technique for vaccine discovery using VLPs. This strategy, analogous to filamentous phage display, allows bacteriophage VLP-based vaccines to be identified from a vast library of potential vaccines by affinity selection. This technology integrates epitope discovery and immunization functions into a single platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.